Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
Xiao-I (NASDAQ: AIXI) and ABB (SIX: ABBN) Forge Strategic Partnership to Drive Industrial Digital Intelligence Advancement with Hua Zang Universal Large Language Model